DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20202730

Evaluation of efficacy of injection ferric carboxymaltose in pregnant women

Rupali M. Sabale, Reena J. Wani, Rashmi Jalvee

Abstract


Background: Iron deficiency anaemia (IDA) continues to be a very common problem in developing countries leading to a spectrum of adverse events in pregnant women. The objective of this study was to determine the efficacy, side effects and tolerance of ferric carboxymaltose as compared to available iron preparations for the prophylaxis and treatment of mild to moderate iron deficiency anaemia during pregnancy.

Methods: One-year clinical study (from June 2017 to May 2018). A total 100 patients were enrolled after matching inclusion and exclusion criteria. The efficacy assessment was performed during 4, 8, and 12 weeks of starting therapy. If the patient is not responding to therapy in either arm as documented by no rise or fall in haemoglobin levels patients may be removed from study for other therapy. Treatment duration up to 12 weeks. Safety and efficacy follow-up visit at 4, 8 and 12 weeks. Institutional ethics committee permission was taken.

Results: On intra-group comparisons there was significant increase in haemoglobin levels at 8 and 12 weeks in oral iron group as compared to day 1 haemoglobin levels while there was significant increase in haemoglobin levels at 4, 8 and 12 weeks in IV iron group as compared to day 1 haemoglobin levels. On intergroup comparisons between oral and IV iron group, there was significant increase in haemoglobin levels at 4, 8 and 12 weeks in IV iron group as compared oral iron group haemoglobin levels.

Conclusions: Intravenous iron therapy with ferric carboxymaltose causes significant improvement in haemoglobin more quickly and more effective in correcting iron deficiency anaemia in pregnancy compared to oral treatment in terms of increase in haemoglobin levels at 4, 8 and 12 weeks. Intravenous ferric carboxymaltose is safe and effective option for pregnant women with iron deficiency anaemia.


Keywords


Injection ferric carboxymaltose, Iron deficiency anaemia

Full Text:

PDF

References


Traina F. Iron deficiency in patients submitted to gastric or intestinal resection: prevalence, causes, clinical repercussions, diagnostic approach and prevention. Rev Bras Hematol Hemoter. 2010;32:78-83.

Cançado RD, Lobo C, Friedrich JR. Treatment of iron-deficiency anemia with parenteral iron. Rev Bras Hematol Hemoter. 2010;32:121-8.

Cançado RD, Brasil SA, Noronha TG, Chiattone CS. Evaluation of the efficacy of intravenous use of iron hydroxide saccharate III in the treatment of adult patients with iron deficiency anemia. Rev Bras Hematol Hemoter. 2007;29(2):123-9.

Cançado RD, Brasil SA, Noronha TG, Chiattone CS. Intravenous use of iron hydroxide saccharate III impatient with anemia-iron deficiency. Rev Assoc Med Bras. 2005;51(6):323-8.

Muñoz M, Gómez-Ramírez S, García-Erce JA. Intravenous iron in inflammatory Bowell disease. World J Gastroenterol. 2009;15(37):4666-74.

Erichsen K, Ulvik RJ, Nysaeter G, Johansen J, Ostborg J, Berstad A. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol. 2005;40(9):1058-65.

Gasche C, Waldhoer T, Feichtenschlager T, Male C, Mayer A, Mittermaier C. Prediction of response to iron sucrose in inflammatory bowel disease-associated anaemia. Am J Gastroenterol. 2001;96(8):2382-7.

Gisbert JP, Bermejo F, Pajares R, Perez-Calle JL, Rodriguez M, Algaba A. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflam Bowel Dis. 2009;15(10):1485-91.

Lyseng-Williamsom KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009;69(6):739-56.

Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC. A novel intravenous iron formulation for treatment of anaemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008;103(5):1182-92.

Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-48.

Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anaemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49(12):2719-28.

Covic A, Mircescu G. The safety and efficacy of intravenous iron carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol Dial Transplant. 2010;25(8):2722-730.

Shill KB, Karmakar P, Kibria G, Das A, Rahman MA, Hossain MS, et al. Prevalence of iron-deficiency anaemia among university students in Noakhali region, Bangladesh. J Health Popul Nutr. 2014;32:103-10.

Haniff J, Das A, Onn LT. Anaemia in pregnancy in Malaysia: a cross-sectional survey. Asia Pacific J Clin Nutrit. 2007;16(3):527-36.

Singh K, Fong YF, Kuperan P. A comparison between intravenous iron polymaltose complex (Ferrum Hausmann) and oral ferrous fumarate in the treatment of iron deficiency anaemia in pregnancy. Eur J Haematol. 1998;60:119-24.

Shafi D, Purandare Shekhar V, Sathe AV. Iron deficiency anaemia in pregnancy: intravenous versus oral route. The J Obstet Gynecol India. 2012;62(3):317-21.

Al-Momen AK, al-Meshari A, al-Nuaim L, Saddique A, Abotalib Z, Khashogji T, et al. Intravenous iron sucrose complex in the treatment of iron deficiency anaemia during pregnancy. Eur J Obstet Gynecol Reprod Biol. 1996;69:121-4.

Goodnough LT, Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anaemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49(12):2719-28.

Al RA, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, Haberal A. Intravenous versus oral iron for treatment of anaemia in pregnancy: a randomized trial. Obstet Gynecol. 2005;106:1335-40.